Name of Principal Investigator - Title
Name of Principal Investigator - First name
Name of Principal Investigator - Last name
Address of institution -Institution
ISPED / INSERM U1219 / Université de Bordeaux
Address of institution - Street address
Address of institution - City
Address of institution - Postcode
IPSEN France, Novartis Pharma France, CNSA (Caisse Nationale de Solidarité et dAutonomie), Roche
Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?
Alzheimer's disease and other dementias| Parkinson's disease
Q1b. When are studies on the above condition(s) expected to become possible?
Q2a. In a single sentence what is the stated aim of the cohort?
To study cerebral and functional ageing
Q2b. What distinguishes this cohort from other population cohorts?
Q3a. i) Number of publications that involve use of your cohort to date
Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:
Q4a. Study criteria: what is the age range of participants at recruitment? To:
Q4b. Study criteria: what are the inclusion criteria?
65 or more years old subjects, living at home and randomly selected from the electoral rolls in 75 different sites of two French administrative districts
Q4c. Study criteria: what are the exclusion criteria?
Q5. What is the size of the cohort (i.e. how many participants have enrolled)?
Q6a. Please describe what measures are used to characterise participants
Sociodemographic characteristics, lifestyle, medical antecedents, medications, depressive symptomatology and activity limitations were assessed at baseline and each follow-up time. A complete cognitive evaluation with systematic screening for dementia was performed at baseline and each follow-up time.
Q6b. Are there additional measures for participants with a clinical disorder?
Examination by a neurologist or a geriatrician
Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?
If yes please specify
Primary endpoint: dementia; secondary endpoint: functional evaluation
Q7. What is the study design (select all that apply)?
Prospective cohort| Longitudinal
Q8. Are your cases matched by
Q9a. Does your study include a specialised subset of control participants?
Q9b. If your study includes a specialised subset of control participants please describe
Participants free of the disease can be used as controls
Q10a. i) Please enter the data collection start date
Q10a. ii) Please enter the data collection end date
Last follow-up: 2016; however a next follow-up is planned
Q10a. iii) Is data collection for this study
Data collection ongoing| Data analysis ongoing| Closed to new patients
Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?
Yes - intend to apply for funding
Other please specify here
Mainly through the study + link with cancer registry
Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?
Yes (participants given permission to be re-contacted via PIs)
Q13a. Please give information on the format and availability of data stored in a database (1)
Data summarised in database
Q13a. Please give information on the format and availability of data stored in a database (2)
Q13a. Please give information on the format and availability of data stored in a database (3)
Q13a. Please give information on the format and availability of data stored in a database (4)
Q13b. Please give information on the format and availability of data held as individual records (1)
Data is held as individual records
Q13b. Please give information on the format and availability of data held as individual records (2)
Q13b. Please give information on the format and availability of data held as individual records (3)
Data held on computer based records
Q13b. Please give information on the format and availability of data held as individual records (4)
Please specify language used
Q14a. Is data available to other groups?
Q14b. If data is available to other groups what is the access policy/mechanisms for access?
Apply to PI or co-ordinator at resource| Access independent of collaboration with PI
Q15. What data sharing policy is specified as a condition of use?
Q16a. Are tissues/samples/DNA available to other groups?
Q16b i) If yes, please describe below:
Q16b. ii) In what form are tissues/samples/DNA supplied?
Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?
Q17. Is information on biological characteristics available to other groups?
Types: Population Cohorts
Member States: France
Diseases: Alzheimer's disease & other dementias, Parkinson's disease & PD-related disorders
Database Categories: N/A
Database Tags: N/A
Export as PDF